IRIS
CIANI, ORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.117
NA - Nord America 9.941
AS - Asia 5.350
SA - Sud America 704
Continente sconosciuto - Info sul continente non disponibili 512
AF - Africa 182
OC - Oceania 35
Totale 28.841
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.496
IT - Italia 3.742
RU - Federazione Russa 2.989
FI - Finlandia 1.641
CN - Cina 1.601
SG - Singapore 1.412
IE - Irlanda 1.112
GB - Regno Unito 585
VN - Vietnam 554
BR - Brasile 538
UA - Ucraina 429
DE - Germania 426
HK - Hong Kong 419
CA - Canada 320
FR - Francia 317
BD - Bangladesh 297
SE - Svezia 247
TR - Turchia 226
IN - India 172
NL - Olanda 164
KR - Corea 156
ZA - Sudafrica 94
ID - Indonesia 79
MX - Messico 76
IL - Israele 72
PL - Polonia 68
BG - Bulgaria 58
CZ - Repubblica Ceca 55
KZ - Kazakistan 54
ES - Italia 51
AR - Argentina 46
IQ - Iraq 46
JP - Giappone 43
BE - Belgio 39
PK - Pakistan 37
AU - Australia 30
AT - Austria 28
EC - Ecuador 28
VE - Venezuela 28
IR - Iran 25
RO - Romania 24
MA - Marocco 21
PT - Portogallo 21
AE - Emirati Arabi Uniti 20
CH - Svizzera 20
CO - Colombia 20
LT - Lituania 18
PH - Filippine 18
EU - Europa 17
CL - Cile 16
MY - Malesia 14
TN - Tunisia 14
UZ - Uzbekistan 14
DK - Danimarca 13
EG - Egitto 13
KE - Kenya 13
AZ - Azerbaigian 12
PE - Perù 12
SA - Arabia Saudita 12
HU - Ungheria 9
JO - Giordania 9
LV - Lettonia 9
NO - Norvegia 9
CR - Costa Rica 8
GR - Grecia 8
JM - Giamaica 8
TT - Trinidad e Tobago 8
TH - Thailandia 7
HN - Honduras 6
KG - Kirghizistan 6
OM - Oman 6
SN - Senegal 6
UY - Uruguay 6
BO - Bolivia 5
DZ - Algeria 5
LA - Repubblica Popolare Democratica del Laos 5
NG - Nigeria 5
PY - Paraguay 5
AL - Albania 4
BY - Bielorussia 4
ET - Etiopia 4
LU - Lussemburgo 4
MD - Moldavia 4
NP - Nepal 4
SI - Slovenia 4
SV - El Salvador 4
TW - Taiwan 4
AD - Andorra 3
AM - Armenia 3
BH - Bahrain 3
GE - Georgia 3
LK - Sri Lanka 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EE - Estonia 2
Totale 28.313
Salva come PNG Salva come JPEG
Città #
Helsinki 1.533
Ashburn 1.424
San Jose 1.114
Dublin 1.108
Milan 773
Singapore 683
Chandler 673
Moscow 611
Hefei 553
Dallas 477
Council Bluffs 470
Hong Kong 411
Beijing 351
Jacksonville 335
New York 293
Rome 292
Ann Arbor 258
Los Angeles 215
Southend 215
Toronto 208
The Dalles 175
Edison 166
Columbus 160
Redmond 149
Seoul 149
Dearborn 146
Ho Chi Minh City 144
Lauterbourg 137
Houston 134
Dong Ket 130
Wilmington 116
Hanoi 107
Boston 103
Modena 98
Lawrence 97
Boardman 92
Buffalo 86
Naples 85
Johannesburg 84
Munich 80
Izmir 71
Frankfurt am Main 68
Jakarta 68
São Paulo 66
Tel Aviv 66
Santa Clara 65
Bologna 58
Orem 52
Almaty 50
Redwood City 50
Seattle 50
Mountain View 48
Palombara Sabina 47
Warsaw 47
Lappeenranta 46
Chennai 44
Turin 41
Florence 40
Phoenix 40
Woodbridge 40
Atlanta 39
Genoa 39
Montreal 38
Tokyo 38
Chicago 37
Fairfield 36
Bari 34
San Francisco 34
Mexico City 33
Brooklyn 32
Brussels 31
Poplar 31
Catania 30
Denver 30
London 30
Nuremberg 30
Stockholm 29
Washington 28
Fremont 27
Amsterdam 24
Ottawa 24
Da Nang 22
Belo Horizonte 20
Brno 20
Guangzhou 20
Verona 19
Ankara 18
Assago 18
Brescia 18
Palermo 18
Bucharest 16
Düsseldorf 16
Kunming 16
Mumbai 16
Nanjing 16
Rio de Janeiro 16
Trieste 16
Falkenstein 15
Vienna 15
West Jordan 15
Totale 16.496
Salva come PNG Salva come JPEG
Nome #
EQ-5D-5L population norms for Italy 654
Esiti di salute e performance del Servizio Sanitario Nazionale 482
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 465
La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato? 438
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 394
I dispositivi medici in Italia: un settore, tanti mercati 349
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 329
Gli esiti di salute del Servizio Sanitario Nazionale 320
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 319
Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis 319
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration 306
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 291
La dimensione del settore dei dispositivi medici 279
Programma nazionale HTA per dispositivi medici: quali sfide per l’implementazione? 279
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 279
An economic perspective on urinary tract infection: the "costs of resignation" 274
An electronic patient-reported outcome mobile app for data collection in type a hemophilia: design and usability study 263
Gli esiti di salute del Servizio Sanitario Nazionale 255
Myth #5: health care is rightly left to the private sector, for the sake of efficiency 255
A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study 252
Current and Future Trends in the HTA of Medical Devices 251
Surrogate endpoints: a key concept in clinical epidemiology 250
Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis 249
Endpoint surrogati e politiche sanitarie: l’importanza di metodi di validazione adeguati 248
A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement 244
Integrating HTA principles into procurement of medical devices: the Italian national HTA programme for medical devices 241
Early budget impact analysis of magnetic balloon technology for facilitating the completion of difficult colonoscopies 232
A repeated cross-sectional analysis on the economic impact of SARS-CoV-2 pandemic at the hospital level in Italy 231
A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis 230
Broadening the concept of value: a scoping review on the option value of medical technologies 230
Hospital-based HTA: quale valore per la valutazione delle tecnologie nelle Aziende Sanitarie italiane? 228
Distinguishing features in the assessment of mHealth apps 225
I processi di valutazione dei dispositivi medici e delle tecnologie sanitarie 224
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses 223
Mapping payment and pricing schemes for health innovation: protocol of a scoping literature review 220
Surrogate endpoints in trials-a call for better reporting 216
Value-based healthcare: il nuovo approccio di AIFA alla determinazione multidimensionale del valore 214
A more evidence based approach to the use of surrogate end points in policy making 212
Coverage with evidence development for medical devices in Europe: can practice meet theory? 212
The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 211
Measuring value in health care: a comparative analysis of value-based frameworks 207
Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma 206
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal 206
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges 205
Esiti di salute e performance del Servizio Sanitario Nazionale 204
La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia 204
European diabetes research and its funding, 2002–2013 203
Esiti di salute e performance del Servizio Sanitario Nazionale 200
Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: results from the PRO4All project 199
Valutare l’impatto dell’HTA come strumento di governo dell’innovazione tecnologica: modelli teorici e studi empirici 199
Harnessing digital health technologies during and after the COVID-19 pandemic: context matters 198
Strumenti a supporto del processo decisionale condiviso in oncologia 196
Assessment of nonfatal myocardial infarction as a surrogate for all-cause and cardiovascular mortality in treatment or prevention of coronary artery disease: a meta-analysis of randomized clinical trials 195
Surrogate endpoints in health technology assessment: an international review of methodological guidelines 194
Esiti di salute e performance del Servizio Sanitario Nazionale 193
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis 192
Corona-regionalism? Differences in regional responses to COVID-19 in Italy 192
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer 191
Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials 190
Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. 188
Implementing shared decision-making interventions in breast cancer clinical practice: a scoping review 185
An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations 181
Design and features of pricing and payment schemes for health technologies: a scoping review and a proposal for a flexible need-driven classification 181
Comparing drug and non-drug technologies in comparative effectiveness research 181
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? 179
Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany 179
The Coronavirus pandemic and inequality in Italy 178
Core outcome set in surgical oncology: why, what and how to measure 178
Valorizzare gli esiti riferiti dal paziente : opportunità e sfide 175
The impact of surgical experience in VATS lobectomy on conversion and patient quality of life: results from a comprehensive national video-assisted thoracic surgical database 174
Esiti di salute e performance del Servizio Sanitario Nazionale 174
Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments 173
Mud-bath therapy in addition to usual care in bilateral knee osteoarthritis: economic evaluation alongside a randomized controlled trial 173
A call for better reporting of trials using surrogate primary endpoints 172
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients 170
Introduction to economic evaluation and health technology assessment 170
Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? 169
Time to review the role of surrogate end points in health policy: state of the art and the way forward 167
Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments 167
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials 166
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 162
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers 160
The development of an Archive of Patient-Reported Outcome Measures (PROMs) in Oncology: The Italian PRO4All Project 157
Validation of exercise capacity as a surrogate endpoint in exercise-based rehabilitation for heart failure: a meta-analysis of randomized controlled trials 157
Exercise training for chronic heart failure (ExTraMATCH II): why all data are not equal 157
A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) Collaboration 155
Surrogate endpoints in randomised trials of physiotherapy interventions: the SPIRIT and CONSORT extension checklists for better reporting 154
The impacts of diabetes research from 31 European Countries in 2002 to 2013 153
Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps 153
Machine learning-assisted health economics and policy reviews: a comparative assessment 152
The evaluation of medical devices: are we getting closer to solve the puzzle? A review of recent trends 152
Determinants of demand for total hip and and knee arthroplasty: a systematic literature review 151
Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence 151
Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study 150
The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy 150
Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy 149
Value attribution for combination treatments: two potential solutions for an insoluble problem 147
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study 147
Health technology assessment methods guidelines for medical devices: how can we address the gaps? the international federation of medical and biological engineering perspective 147
The rise of rules: will the new regulation of medical devices make us safer? 145
Totale 21.896
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.632
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.632
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.173 0 0 50 68 140 66 58 233 72 145 143 198
2022/20233.178 202 173 86 266 203 223 83 162 1.398 121 161 100
2023/20242.436 109 142 149 59 258 287 193 324 98 180 303 334
2024/20253.372 108 71 228 172 179 195 276 245 961 384 341 212
2025/202613.021 758 986 365 850 1.023 463 1.387 1.224 3.492 1.542 586 345
2026/20271.455 540 708 207 0 0 0 0 0 0 0 0 0
Totale 28.841